Huron Consulting Group Inc.
07/27/2026 | Press release | Distributed by Public on 07/27/2026 15:30
Management Change/Compensation (Form 8-K)
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On and effective July 23, 2026, the Board of Directors (the "Board") of Huron Consulting Group Inc. ("Huron" or the "Company") elected Dr. L. Thomas Richards as a director of Huron, to serve until the 2027 Annual Meeting of Stockholders of Huron (the "2027 Annual Meeting"). Dr. Richards has been appointed to the Company's Nominating and Corporate Governance Committee, Finance and Capital Allocation Committee and Technology and Information Security Committee, effective July 23, 2026. Dr. Richards will stand for re-election at the 2027 Annual Meeting.
Dr. Richards most recently served as Chair of the Board of Directors of WittKieffer, an executive search and leadership advisory professional services firm serving the healthcare, higher education and life sciences sectors. He has also served in a variety of roles across the life sciences industry with a focus on emerging technologies and innovation-driven growth, including as Interim Chief Executive Officer of One BioMed, a molecular tools company and Chief Executive Officer of TessArae, a molecular diagnostics company. In addition, he recently served as a Senior Advisor to Metis Genetics, a technology-enabled genetic counseling company, One BioMed, and Nanomix, a point-of-care diagnostic testing company, and advises venture capital and private equity investors across the life sciences industry. Dr. Richards also practiced academic medicine as an emergency physician and assistant professor at Stanford University and the University of California, San Francisco.
Earlier in his career, he was an investment banker in the mergers and acquisitions (M&A) groups of Lazard Frères, UBS and SG Cowen. Dr. Richards previously served on the board of directors of Cowen Group, Inc., a publicly traded financial services firm, and has served as a director of TessArae and One BioMed. He also currently serves on the boards of two non-profit organizations, The World Telehealth Initiative and the Surfrider Foundation. Dr. Richards received an M.D. from Harvard Medical School, an M.Phil. from the University of Sydney, and a B.A. from Yale University. He is a board-certified physician in Emergency Medicine.
As a director of Huron, Dr. Richards will receive compensation in accordance with the Company's non-employee director compensation practices described in the Company's 2026 Annual Proxy Statement filed with the Securities and Exchange Commission on March 20, 2026. This compensation generally consists of an annual cash retainer in the amount of $80,000, an annual retainer of $7,500 for service on the Nominating and Corporate Governance Committee of the Board, an annual retainer of $7,500 for service on the Finance and Capital Allocation Committee of the Board, an annual retainer of $7,500 for service on the Technology and Information Security Committee of the Board, and an annual grant of restricted stock on the date of the Company's annual meeting with a value of $180,000. Because Dr. Richards joined the Company within the six months following the Company's annual meeting, Dr. Richards's annual grant of restricted stock will be prorated such that Dr. Richards will receive half of the annual grant, which will be granted on August 1, 2026, and will vest fully on the first anniversary of the grant. Dr. Richards's initial cash retainer will also be prorated to reflect his appointment date.
There are no arrangements or understandings between Dr. Richards and any other persons pursuant to which he was elected as a director. Dr. Richards has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.
Huron Consulting Group Inc. published this content on July 27, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on July 27, 2026 at 21:30 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]